Femoral Fractures
3
Pipeline Programs
2
Companies
2
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
+ 1 programs with unclassified modality
On Market (1)
Approved therapies currently available
TYMLOSApproved
abaloparatide
Radius HealthParathyroid Hormone-Related Peptide Analog [EPC]subcutaneous2017
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Radius HealthAbaloparatide
PfizerTranexamic Acid plus standard of care
Clinical Trials (2)
Total enrollment: 82 patients across 2 trials
Supracondylar Distal Femur Fractures and Abaloparatide
Start: Jun 2024Est. completion: Jun 2025
Phase 4Withdrawn
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture
Start: Apr 2009Est. completion: Jun 201082 patients
Phase 4Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Peptide is the dominant modality (100% of programs)
2 companies competing in this space